Jeffrey A. Cohen
Mellen Center for MS Treatment and Research, Cleveland Clinic · Dartmouth-Hitchcock Medical Center · The Cleveland Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeffrey A. Cohen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:03 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04047628 · Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)National Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · study chair
- Ph2NCT02090725 · Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)Jeffrey A. Cohen, MD · terminated · Muscle Weakness · principal investigator
- Ph1NCT00813969 · Autologous Mesenchymal Stem Cell (MSC) Transplantation in MSThe Cleveland Clinic · completed · Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Ph4NCT00112034 · AVONEX® Combination Trial - "ACT"Biogen · completed · Multiple Sclerosis, Relapsing-Remitting · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 21 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Immunobiology of mesenchymal stem cell transplantation in multiple sclerosisR01NS074787 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2011 to 2014 · $297,653 awarded in 2014Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Immune Tolerance NetworkUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · fiscal years 2014 to 2026Named on NCT04047628
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:03 UTC. The ranking covers the 200 most relevant of 105 PubMed records, and a shared surname and initials can bring in a namesake. All 105 on PubMed
- 1,718 citationsRCR 47.2
- 1,539 citationsRCR 42.1
- 941 citationsRCR 29.8
- 926 citationsRCR 28.2
- Ofatumumab versus Teriflunomide in Multiple Sclerosis.N Engl J Med · 2020598 citationsRCR 30.4
- Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls.Mult Scler · 2008562 citationsRCR 22.4
- A multisite, randomized controlled trial for children with sexual abuse-related PTSD symptoms.J Am Acad Child Adolesc Psychiatry · 2004510 citationsRCR 18.4
- 375 citationsRCR 9.5
- 310 citationsRCR 7.9
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.Lancet Neurol · 2019234 citationsRCR 11.2